Cancer Reprogramming
Our cancer reprogramming technology represents a first-in-class therapeutic approach that specifically targets cancer cells through epigenetic mechanisms. This innovative strategy aims to reprogram cancer cells while sparing healthy tissue.
What is Partial Reprogramming?
The Problem: Current Treatment Limitations
Treatment Failures
- •Drug resistance develops in 20-80% of cases
- •Toxicity and severe side effects limit treatment options
- •Low survival rates in aggressive cancers (< 5% in GBM[4])
- •Limited options for metastatic disease
Market Opportunity
- Global oncology market exceeds $200B
- Market growing at 8.9% CAGR (2024-2033)
- Glioblastoma treatment market: $2.8B in 2024
- Urgent need for novel treatment approaches
Our Approach: Cancer Reprogramming Technology
The Epigenetic Problem
- • Cancer cells proliferate without control
- • Blocked epigenetic state enables self-renewal
- • Traditional therapies fail to address root cause
Our Solution
- • Alter cancer cell epigenome through reprogramming
- • Re-differentiation overcomes epigenetic blocks
- • Cancer cells become senescent and die naturally
Key Advantages
- • Overcomes drug resistance
- • Universal application across cancer types
- • Minimal impact on healthy cells
The Process: Cancer cell epigenome is altered by reprogramming treatment → Re-differentiation overcomes the epigenetic block → Cancer cells differentiate into a less malignant, senescent form → Most fully differentiated cells die through apoptosis due to high mutational burden.
Revolutionary Approach
We've developed a revolutionary approach to cancer treatment through epigenetic reprogramming that specifically targets cancer cells. Our technology uniquely induces senescent apoptosis naturally in cancer cells, representing a first-in-class therapeutic strategy.
High Impact
Our approach demonstrates unprecedented effects across multiple cancer cell lines, with particular efficacy in brain cancer models. By modulating specific epigenetic pathways, we can:
- •Reverse malignant cellular programming
- •Induce natural senescent anaphylaxis
- •Target therapy-resistant cancer cells
- •Prevent metastasis
- •Control tumor growth and invasion
Comprehensive Cancer Control
Our therapeutic approach simultaneously addresses multiple aspects of cancer biology:
Precision Targeting
Cancer-specific epigenetic modifications
Safety First
Minimal impact on healthy cells
Brain Cancer Focus
Optimized for glioblastoma treatment
Broad Effects on Aging Hallmarks
Epigenetic rejuvenation impacts multiple hallmarks of aging, addressing the fundamental mechanisms that drive age-related diseases and cancer:
Genomic Stability
Reduces DNA damage and enhances DNA repair mechanisms.
Proteostasis
Improves protein folding, reduces protein aggregation, and enhances autophagy.
Mitochondrial Function
Restores mitochondrial efficiency, reducing oxidative stress and improving energy production.
Cellular Senescence
Decreases the number of senescent cells, reducing chronic inflammation and promoting tissue regeneration.
Stem Cell Function
Enhances the function and proliferative capacity of stem cells, supporting tissue repair and regeneration.
Core IP Platform: Protein Drug Engineering
Our proprietary platform combines engineered protein drugs with advanced screening technologies for safe and effective reprogramming.
Engineered Protein Drug
- •Novel OCT4 variants optimized for rejuvenation
- •Enhanced safety and efficiency profiles
- •Minimal size with maximal function
Screening Platform
- •Proprietary microfluidic devices
- •High-throughput functional validation
- •Quantitative biomarker assessment
Applications & Methods
- •Vascular rejuvenation protocols
- •Cell-type specific targeting
- •Delivery systems optimization
Delivery Platforms
Our delivery strategy consists of multiple complementary platforms, each optimized for specific therapeutic applications and patient needs.
mRNA Platform
Our mRNA platform represents the cutting edge of therapeutic delivery technology. We've developed novel delivery vehicles based on phase separation technology, enabling precise and efficient delivery of reprogramming factors to cancer cells.
- •Phase separation-based delivery vehicles
- •Targeted delivery to cancer cells
- •Minimal off-target effects
- •Optimized for maximum efficacy
Cell Therapy
Our cell therapy platform complements our mRNA approach, providing an additional avenue for delivering cancer reprogramming factors. Optimized for maximum efficacy and safety in targeting various cancer types.
- •Advanced engineering techniques
- •Precise targeting capabilities
- •Optimized for brain cancer applications
- •Superior therapeutic outcomes
Organ-on-a-Chip
Our organ-on-a-chip technology simulates human organ systems in vitro, providing a platform to study the effects of epigenetic rejuvenation in a controlled environment.
- •High-throughput screening
- •Detailed mechanistic studies
- •Accelerated drug development
- •Human-relevant models
Epigenetic Reprogramming Pipeline
Our partial reprogramming programs are advancing through pre-clinical development, targeting various cancer indications and neurological conditions.
Cancer
Brain (GBM)
E-ON-001
Cancer
Multiple indications
E-ON-002
Neurology/Vasculature
Neurodegeneration
E-NE-001
Key Takeaways
- First-in-class cancer treatment targeting the epigenetic root cause of cancer, not just symptoms
- Overcomes drug resistance by reprogramming cancer cells to naturally undergo senescence and apoptosis
- Dual delivery platforms (mRNA and cell therapy) optimized for brain cancer with minimal impact on healthy cells
- Addresses $200B+ oncology market with breakthrough therapy for treatment-resistant cancers like glioblastoma
- Currently in pre-clinical development with three active programs targeting cancer and neurodegeneration
Scientific References
Reprogramming to recover youthful epigenetic information and restore vision
Lu Y, Brommer B, Tian X, et al. (2020)
Nature
Partial reprogramming induces a steady decline in epigenetic age before loss of somatic identity
Sarkar TJ, Quarta M, Mukherjee S, et al. (2020)
Aging Cell
Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells
Gill D, Parry A, Santos F, et al. (2022)
Nature Communications